TherapeuticsMD, Inc. (TXMD) stock
TXMDNasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 13, 2026Score 12/3026% below fair value
$1.91+0.10 (+5.52%)
Close on Nov 17, 2026Market cap $22.11MP/E –Yield –
TherapeuticsMD operating income
Operating income is the profit from the core business after operating expenses such as R&D and selling costs, before interest and taxes.
TherapeuticsMD's operating income for the twelve months ending Jun 30, 2026 was -$3.95M. For fiscal 2025 it was -$4.39M. The highest annual figure on record is $1.19M in fiscal 2022.
Annual operating income
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$4.39M | – |
| FY2024 | Dec 31, 2024 | -$6.11M | – |
| FY2023 | Dec 31, 2023 | -$8.52M | -815.6% |
| FY2022 | Dec 31, 2022 | $1.19M | – |
| FY2021 | Dec 31, 2021 | -$79.58M | – |
| FY2020 | Dec 31, 2020 | -$155.54M | – |
| FY2019 | Dec 31, 2019 | -$151.21M | – |
| FY2018 | Dec 31, 2018 | -$130.22M | – |
| FY2017 | Dec 31, 2017 | -$77.63M | – |
| FY2016 | Dec 31, 2016 | -$90.25M | – |
| FY2015 | Dec 31, 2015 | -$85.19M | – |
| FY2014 | Dec 31, 2014 | -$54.04M | – |
| FY2013 | Dec 31, 2013 | -$25.81M | – |
| FY2012 | Dec 31, 2012 | -$16.15M | – |
| FY2011 | Dec 31, 2011 | -$5.43M | – |
Quarterly operating income
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$816.00K | – |
| Q1 FY2026 | Mar 31, 2026 | -$723.00K | – |
| Q4 FY2025 | Dec 31, 2025 | -$1.55M | – |
| Q3 FY2025 | Sep 30, 2025 | -$862.00K | – |
| Q2 FY2025 | Jun 30, 2025 | -$695.00K | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.28M | – |
| Q4 FY2024 | Dec 31, 2024 | -$652.00K | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.13M | – |
| Q2 FY2024 | Jun 30, 2024 | -$2.79M | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.14M | – |
| Q4 FY2023 | Dec 31, 2023 | -$1.61M | -103.3% |
| Q3 FY2023 | Sep 30, 2023 | -$1.77M | – |
| Q2 FY2023 | Jun 30, 2023 | -$2.47M | – |
| Q1 FY2023 | Mar 31, 2023 | -$2.67M | – |
| Q4 FY2022 | Dec 31, 2022 | $48.44M | – |
| Q3 FY2022 | Sep 30, 2022 | -$14.52M | – |
| Q2 FY2022 | Jun 30, 2022 | -$14.86M | – |
| Q1 FY2022 | Mar 31, 2022 | -$17.88M | – |
| Q4 FY2021 | Dec 31, 2021 | -$35.39M | – |
| Q3 FY2021 | Sep 30, 2021 | -$39.92M | – |
| Q2 FY2021 | Jun 30, 2021 | -$35.18M | – |
| Q1 FY2021 | Mar 31, 2021 | -$29.28M | – |
| Q4 FY2020 | Dec 31, 2020 | -$34.61M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.97M | – |
| Q2 FY2020 | Jun 30, 2020 | -$45.04M | – |
| Q1 FY2020 | Mar 31, 2020 | -$50.92M | – |
| Q4 FY2019 | Dec 31, 2019 | -$44.39M | – |
| Q3 FY2019 | Sep 30, 2019 | -$27.07M | – |
| Q2 FY2019 | Jun 30, 2019 | -$41.64M | – |
| Q1 FY2019 | Mar 31, 2019 | -$38.11M | – |
| Q4 FY2018 | Dec 31, 2018 | -$38.12M | – |
| Q3 FY2018 | Sep 30, 2018 | -$34.36M | – |
| Q2 FY2018 | Jun 30, 2018 | -$33.02M | – |
| Q1 FY2018 | Mar 31, 2018 | -$24.72M | – |
| Q4 FY2017 | Dec 31, 2017 | -$21.68M | – |
| Q3 FY2017 | Sep 30, 2017 | -$14.83M | – |
| Q2 FY2017 | Jun 30, 2017 | -$19.83M | – |
| Q1 FY2017 | Mar 31, 2017 | -$21.29M | – |
| Q4 FY2016 | Dec 31, 2016 | -$22.94M | – |
| Q3 FY2016 | Sep 30, 2016 | -$25.13M | – |
See a number that looks wrong?